Patients must not be known to have AML in the central nervous system (CNS)
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by malignancy
Known central nervous system (CNS) involvement with CLL or T-LGL
Subject has known active central nervous system (CNS) involvement from AML
Known central nervous system (CNS) involvement
Participant has known active central nervous system (CNS) involvement with AML.
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Known central nervous system (CNS) involvement
Known active central nervous system (CNS) involvement
Known active central nervous system (CNS) involvement by MM
Subject has known active central nervous system (CNS) involvement with AML
known active central nervous system (CNS) involvement by malignancy.
History of or known active central nervous system (CNS) involvement with AML
Participant has known Central Nervous System (CNS) involvement with AML.
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Known brain metastases or central nervous system (CNS) involvement
Has known clinically active central nervous system (CNS) involvement
Known central nervous system (CNS) tumor involvement
Known active central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement by leukemia
History of or known active central nervous system (CNS) involvement or leptomeningeal involvement
Known active central nervous system (CNS) involvement with AML at study entry
AML central nervous system (CNS) involvement
Has known clinically active central nervous system (CNS) involvement
Patient must have no known central nervous system (CNS) involvement
AML patients with known, active leptomeningeal/central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by malignancy
Known central nervous system (CNS) involvement
Participant has known active central nervous system (CNS) involvement with AML.
Subjects with known or suspected central nervous system (CNS) involvement are not eligible
Patients with known central nervous system (CNS) involvement are excluded from this clinical trial
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by AML
Patients must not have known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement